Relevance of genetic polymorphism in drug metabolism in the development of new drugs
- 1 November 1989
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 36 (6), 551-554
- https://doi.org/10.1007/bf00637734
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.British Journal of Clinical Pharmacology, 1986
- Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.Published by Wiley ,1986
- The Polymorphic Oxidation of ??-Adrenoceptor AntagonistsClinical Pharmacokinetics, 1986
- Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kineticsEuropean Journal of Clinical Pharmacology, 1986
- Premarketing observational studies of population pharmacokinetics of new drugsClinical Pharmacology & Therapeutics, 1985
- Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralolEuropean Journal of Clinical Pharmacology, 1985
- Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidationGastroenterology, 1983
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.Published by Wiley ,1980